Why Innovative Medicines Should Be a Strategic Priority

Prime Minister Carney has called on Canadians to build—to invest boldly in the projects and systems that will define this country’s next chapter. Innovative medicines should be part of that conversation—not as a cost to be contained, but as a strategic investment that helps to power our workforce and economy. Walk away with actionable insights to:

• Shift the conversation from short-term healthcare expenditures to long-term value creation.
• Examine the link between timely access to innovative medicines, improved health outcomes, and healthcare system resilience.
• Understand how innovative medicines support a more productive workforce, a more resilient economy, and contribute to national security preparedness in an increasingly uncertain world.
• Explore how countries that prioritize life sciences and health innovation are attracting investment, talent, research, and manufacturing capacity.
• Identify the policy conditions required to make Canada a global destination for innovation, clinical trials, and biopharmaceutical investment.

Explore how a modernized approach to innovative medicines can strengthen Canada’s health, economic, security, and innovation objectives for decades to come.